MedDataX Logo

Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

NCT ID: NCT00602186

Last Updated: 2008-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial

NCT06262048

Urinary Retention Postoperative
RECRUITING PHASE2

Effect of Preoperative Tamsulosin on Postoperative Urinary Retention

NCT05753670

Postoperative Retention of Urine
COMPLETED PHASE3

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

NCT04859660

Urinary Retention Postoperative
COMPLETED PHASE2

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

NCT05657990

Urinary Retention
RECRUITING EARLY_PHASE1

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

NCT04232683

Urinary Retention
ACTIVE_NOT_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurogenic Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

taking Tamsulosin

Group Type EXPERIMENTAL

tamsolusin

Intervention Type DRUG

0.4 mg /day

2

taking prasosin

Group Type ACTIVE_COMPARATOR

prazosin

Intervention Type DRUG

1 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tamsolusin

0.4 mg /day

Intervention Type DRUG

prazosin

1 mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Flomax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy females with voiding difficulty with MFR\<12 and post void residual urine\>50cc

Exclusion Criteria

* History of pelvic floor surgury during last 3 month
* Any contraindication for Tamsolusin or prazosin
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tabriz University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tabriz University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

SAKINEH hajebrahimi, MD

Role: STUDY_DIRECTOR

Urology department ofTabriz University of Medical Sciences

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

85-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery
NCT06843538 RECRUITING PHASE3
Comparison of TUSP Versus TURP for Treatment of Benign Prostatic Hyperplasia in a Small Prostate Volume
NCT04912349 UNKNOWN NA
Prevention of Acute Voiding Difficulty After Radical Proctectomy
NCT00606983 COMPLETED PHASE3
The Effect of Tamsulosin on Postoperative Urinary Retention
NCT04682366 TERMINATED PHASE4
Intradetrusor Botox at the Time of Transurethral Resection of the Prostate for Mixed Lower Urinary Tract Symptoms
NCT06531655 WITHDRAWN
Prevention of Post-operative Urinary Retention
NCT02486653 COMPLETED PHASE3
The Risk Factor and Outcome of Transient Incontinence After Prostate Enucleation Surgery
NCT05116592 UNKNOWN
Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin
NCT04994431 TERMINATED PHASE4
Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate
NCT01073241 UNKNOWN NA
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH
NCT06922968 NOT_YET_RECRUITING NA
OUTCOMES of SIMULTANEOUS TRANSURETHRAL PROSTATE and BLADDER TUMOR RESECTION VERSUS TRANSURETHRAL BLADDER TUMOR RESECTION in BLADDER TUMOR with BLADDER PROSTATE HYPERPLASIA
NCT06820502 ACTIVE_NOT_RECRUITING NA
TURP Inpatient With Underactive Bladder With BOO
NCT06944743 RECRUITING NA
Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT
NCT03589196 UNKNOWN NA
Effects of Transcutaneous Perineal Stimulation Versus Anal Stimulation
NCT03587402 COMPLETED NA
Predictors of de Novo Urge Urinary Incontinence After Photoselective Vaporization of the Prostate
NCT02243085 UNKNOWN
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention
NCT02684344 TERMINATED NA
Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial
NCT04781049 COMPLETED NA
Single Center Comparative Trial of Trans-Perineal Laser Ablation Vs Water Vapor Ablation
NCT06794333 COMPLETED NA
Outcomes and Efficacy of Ejaculatory Preserving Transurethral Resection of Prostate
NCT05914519 COMPLETED NA
RANDOMIZED CLINICAL TRIAL COMPARING TRANSURETHRAL PROSTATE RESECTION (TURP) AND ECHOLASER SORACTELITE-TPLA (TRANSPERINEAL LASER ABLATION) IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC OBSTRUCTION
NCT07289243 RECRUITING NA
PUL vs TURP in BPH Patients With Urinary Retention
NCT06037356 RECRUITING NA
Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty
NCT03808155 COMPLETED PHASE4
Pelvic Floor Muscle Training to Treat Urinary Incontinence After Radical Prostatectomy
NCT00239824 COMPLETED NA
Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate
NCT02429219 COMPLETED NA
Prospective RCT on Post Prostatectomy Urine Leak
NCT02367404 UNKNOWN PHASE3